Etofibrate

Etofibrate

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	C10AB09 ( WHO )
Pharmacokinetic data
Metabolism	Hydrolyzed to clofibric acid and niacin
Identifiers
IUPAC name 2-[(pyridin-3-yl)carbonyloxy]ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
CAS Number	31637-97-5  Y
PubChem CID	65777
DrugBank	DB08983  Y
ChemSpider	59197  Y
UNII	23TF67G79M
KEGG	D07187  Y
ChEMBL	ChEMBL358150  Y
CompTox Dashboard (EPA)	DTXSID80185521
ECHA InfoCard	100.046.115
Chemical and physical data
Formula	C18H18ClNO5
Molar mass	363.79 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(OCCOC(=O)C(Oc1ccc(Cl)cc1)(C)C)c2cccnc2
InChI InChI=1S/C18H18ClNO5/c1-18(2,25-15-7-5-14(19)6-8-15)17(22)24-11-10-23-16(21)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3 Y Key:XXRVYAFBUDSLJX-UHFFFAOYSA-N Y
(verify)

Etofibrate is a fibrate. It is a combination of clofibrate and niacin, linked together by an ester bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to controlled-release formulations. ^[1]

References

1. Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA (2001). "Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects". Braz J Med Biol Res. 34 (2): 177–82. doi: 10.1590/S0100-879X2001000200004 . PMID   11175492. Free full text